2018 Q3 Form 10-Q Financial Statement

#000086266818000025 Filed on November 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $2.258M $2.630M
YoY Change -14.12% 12.76%
Cost Of Revenue $1.203M $1.467M
YoY Change -18.0% 17.24%
Gross Profit $1.055M $1.162M
YoY Change -9.21% 7.57%
Gross Profit Margin 46.73% 44.2%
Selling, General & Admin $1.002M $996.5K
YoY Change 0.58% -13.75%
% of Gross Profit 94.98% 85.73%
Research & Development $96.41K $193.1K
YoY Change -50.07% -37.79%
% of Gross Profit 9.14% 16.61%
Depreciation & Amortization $13.19K $11.86K
YoY Change 11.23% -4.19%
% of Gross Profit 1.25% 1.02%
Operating Expenses $1.099M $1.190M
YoY Change -7.64% -18.84%
Operating Profit -$43.40K -$27.27K
YoY Change 59.12% -92.92%
Interest Expense $6.851K $33.45K
YoY Change -79.52% 224.33%
% of Operating Profit
Other Income/Expense, Net -$4.341K -$33.25K
YoY Change -86.94% 224.25%
Pretax Income -$50.00K -$60.00K
YoY Change -16.67% -85.0%
Income Tax
% Of Pretax Income
Net Earnings -$47.74K -$60.52K
YoY Change -21.12% -84.7%
Net Earnings / Revenue -2.11% -2.3%
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 7.415M shares 7.551M shares
Diluted Shares Outstanding 7.415M shares 7.551M shares

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $910.0K $430.0K
YoY Change 111.63% 16.22%
Cash & Equivalents $415.8K $429.9K
Short-Term Investments
Other Short-Term Assets $257.0K $230.5K
YoY Change 11.53% -29.67%
Inventory $1.969M $2.019M
Prepaid Expenses
Receivables $1.422M $1.529M
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.610M $4.209M
YoY Change 9.54% 1.77%
LONG-TERM ASSETS
Property, Plant & Equipment $74.50K $50.56K
YoY Change 47.36% -31.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $835.9K $831.6K
YoY Change 0.52% -15.08%
TOTAL ASSETS
Total Short-Term Assets $4.610M $4.209M
Total Long-Term Assets $835.9K $831.6K
Total Assets $5.446M $5.040M
YoY Change 8.05% -1.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $679.0K $1.017M
YoY Change -33.22% -17.69%
Accrued Expenses $744.2K $1.053M
YoY Change -29.34% -1.95%
Deferred Revenue
YoY Change
Short-Term Debt $201.6K $870.0K
YoY Change -76.83% 210.71%
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $2.321M $3.136M
YoY Change -25.99% 12.97%
LONG-TERM LIABILITIES
Long-Term Debt $20.00K $0.00
YoY Change
Other Long-Term Liabilities $740.0K $780.0K
YoY Change -5.13% -4.88%
Total Long-Term Liabilities $760.3K $780.9K
YoY Change -2.63% -5.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.321M $3.136M
Total Long-Term Liabilities $760.3K $780.9K
Total Liabilities $3.082M $3.917M
YoY Change -21.33% 8.82%
SHAREHOLDERS EQUITY
Retained Earnings -$67.99M -$68.59M
YoY Change -0.87% 0.57%
Common Stock $7.415K $7.551K
YoY Change -1.8% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.365M $1.123M
YoY Change
Total Liabilities & Shareholders Equity $5.446M $5.040M
YoY Change 8.05% -1.46%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$47.74K -$60.52K
YoY Change -21.12% -84.7%
Depreciation, Depletion And Amortization $13.19K $11.86K
YoY Change 11.23% -4.19%
Cash From Operating Activities $11.83K -$170.0K
YoY Change -106.96% 0.0%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$6.506K -$14.71K
YoY Change -55.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $36.07K $75.00K
YoY Change -51.91%
NET CHANGE
Cash From Operating Activities $11.83K -170.0K
Cash From Investing Activities -$6.506K -$14.71K
Cash From Financing Activities $36.07K $75.00K
Net Change In Cash $41.40K -$114.2K
YoY Change -136.24%
FREE CASH FLOW
Cash From Operating Activities $11.83K -$170.0K
Capital Expenditures -$10.00K -$10.00K
Free Cash Flow $21.83K -$160.0K
YoY Change -113.65% -5.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 dei Amendment Flag
AmendmentFlag
false
CY2018Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2018Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2018Q3 dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
CY2018Q3 dei Document Type
DocumentType
10-Q
CY2018Q3 dei Entity Central Index Key
EntityCentralIndexKey
0000862668
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7415329 shares
CY2018Q3 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q4 dei Entity Public Float
EntityPublicFloat
1585000 USD
CY2018Q3 dei Entity Registrant Name
EntityRegistrantName
ESCALON MEDICAL CORP.
CY2018Q2 esmc Accruedinterestrelatedparty
Accruedinterestrelatedparty
112389 USD
CY2017Q3 esmc Increasedecreaseinliabilitiesofdiscontinuedoperations
Increasedecreaseinliabilitiesofdiscontinuedoperations
3281 USD
CY2018Q3 esmc Increasedecreaseinliabilitiesofdiscontinuedoperations
Increasedecreaseinliabilitiesofdiscontinuedoperations
278 USD
CY2018Q3 esmc Maximum Maturity Of Highly Liquid Investments Period
MaximumMaturityOfHighlyLiquidInvestmentsPeriod
P90D
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
528844 USD
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
678997 USD
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1387133 USD
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1422476 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
874421 USD
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
744164 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69702043 USD
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69702043 USD
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
502000 shares
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4513000 shares
CY2018Q2 us-gaap Assets
Assets
5426793 USD
CY2018Q3 us-gaap Assets
Assets
5446046 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
4584169 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
4610102 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
544118 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
429885 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
874002 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
914616 USD
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
544118 USD
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
429885 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1124002 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1165397 USD
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-114233 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41395 USD
CY2018Q3 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
4300000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000 shares
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000 shares
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7415329 shares
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7415329 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7415329 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7415329 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
7415 USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
7415 USD
CY2017Q3 us-gaap Concentration Risk Credit Risk Financial Instruments
ConcentrationRiskCreditRiskFinancialInstruments
0.11
CY2018Q3 us-gaap Concentration Risk Credit Risk Financial Instruments
ConcentrationRiskCreditRiskFinancialInstruments
0.12
CY2017Q3 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
0.38
CY2018Q3 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
0.36
CY2018Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2.15 shares
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1467310 USD
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1203133 USD
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
2656896 USD
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
2301778 USD
CY2018Q2 us-gaap Deferred Revenue
DeferredRevenue
481000 USD
CY2018Q3 us-gaap Deferred Revenue
DeferredRevenue
498000 USD
CY2018Q3 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
252000 USD
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
481180 USD
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
498286 USD
CY2018Q3 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
235000 USD
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11855 USD
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13186 USD
CY2018Q3 us-gaap Dividends
Dividends
13005 USD
CY2018Q1 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.03
CY2018Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.01
CY2018Q2 us-gaap Inventory Net
InventoryNet
1823000 USD
CY2018Q2 us-gaap Inventory Net
InventoryNet
1823414 USD
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
199 USD
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2510 USD
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2018Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.3670
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
161350 USD
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
156437 USD
CY2017Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2017Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2017Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3061 USD
CY2018Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
19896 USD
CY2017Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
45532 USD
CY2018Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
35343 USD
CY2017Q3 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
59811 USD
CY2018Q3 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
17106 USD
CY2017Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
100948 USD
CY2018Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-58232 USD
CY2017Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
20922 USD
CY2018Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7427 USD
CY2017Q3 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
-18490 USD
CY2018Q3 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
-6360 USD
CY2018Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
605006 USD
CY2018Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
605006 USD
CY2017Q3 us-gaap Interest Expense
InterestExpense
33448 USD
CY2018Q3 us-gaap Interest Expense
InterestExpense
6851 USD
CY2017Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
23112 USD
CY2018Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0 USD
CY2017Q3 us-gaap Interest Paid
InterestPaid
10587 USD
CY2018Q3 us-gaap Interest Paid
InterestPaid
35648 USD
CY2018Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
978000 USD
CY2018Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
912000 USD
CY2018Q3 us-gaap Inventory Net
InventoryNet
1765000 USD
CY2018Q3 us-gaap Inventory Net
InventoryNet
1765182 USD
CY2018Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
653000 USD
CY2018Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
616000 USD
CY2018Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
192000 USD
CY2018Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
240000 USD
CY2018Q2 us-gaap Liabilities
Liabilities
3014538 USD
CY2018Q3 us-gaap Liabilities
Liabilities
3081527 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5426793 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5446046 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2247021 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2321214 USD
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
767517 USD
CY2018Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
760313 USD
CY2018Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
92532 USD
CY2018Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
92810 USD
CY2018Q2 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
165000 USD
CY2018Q3 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
201575 USD
CY2017Q3 us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
10336 USD
CY2018Q3 us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
6581 USD
CY2017Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75000 USD
CY2018Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
36069 USD
CY2017Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-14706 USD
CY2018Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6506 USD
CY2017Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-174527 USD
CY2018Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
11832 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-60521 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-47736 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60521 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60741 USD
CY2018Q3 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-60741 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33249 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4341 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27272 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43395 USD
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1373382 USD
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
273275 USD
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
183892 USD
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
178535 USD
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
182972 USD
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
268469 USD
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
286239 USD
CY2018Q2 us-gaap Other Assets Current
OtherAssetsCurrent
249620 USD
CY2018Q3 us-gaap Other Assets Current
OtherAssetsCurrent
257047 USD
CY2018Q2 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
18037 USD
CY2018Q3 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
17193 USD
CY2018Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
3153 USD
CY2018Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
3491 USD
CY2017Q3 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
12500 USD
CY2018Q3 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
0 USD
CY2017Q3 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2206 USD
CY2018Q3 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
6506 USD
CY2018Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
101891 USD
CY2018Q3 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
101891 USD
CY2018Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
749480 USD
CY2018Q3 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
743120 USD
CY2018 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
19368 USD
CY2018Q3 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
32373 USD
CY2017Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
CY2018Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
13005 USD
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
645000 USD
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
645000 USD
CY2017Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
100000 USD
CY2018Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2018Q3 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
36575 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
76268 USD
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74501 USD
CY2017Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
545000 USD
CY2018Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
100000 USD
CY2018Q2 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
645000 USD
CY2018Q3 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.013
CY2018Q3 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
201575 USD
CY2017Q3 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
25000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
193081 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96408 USD
CY2017Q2 us-gaap Restricted Cash
RestrictedCash
0 USD
CY2017Q3 us-gaap Restricted Cash
RestrictedCash
0 USD
CY2018Q2 us-gaap Restricted Cash
RestrictedCash
250000 USD
CY2018Q3 us-gaap Restricted Cash
RestrictedCash
250781 USD
CY2018Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
250000 USD
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
250781 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67942203 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67989939 USD
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2426624 USD
CY2018Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2022383 USD
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
2629624 USD
CY2018Q3 us-gaap Sales Revenue Net
SalesRevenueNet
2258383 USD
CY2017Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
203000 USD
CY2018Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
236000 USD
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
996505 USD
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1002237 USD
CY2018Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
165000 USD
CY2018Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
201575 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
2412255 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
2364519 USD
CY2018Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7551430 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7415329 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7551430 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
CY2018Q3 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the &#8220;Company&#8221; collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (&#8220;Sonomed&#8221;), Escalon Digital Solutions, Inc. (&#8220;EMI&#8221;), Escalon Holdings, Inc. (&#8220;EHI&#8221;), Escalon IP Holdings, Inc., and Sonomed IP Holdings, Inc.. All intercompany accounts and transactions have been eliminated. </font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;"></font><font style="font-family:inherit;font-size:10pt;">The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the &#8220;FDA&#8221;). The FDA and other government authorities requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Security and Exchange Commission, and reflect all adjustments (consisting of only normal and recurring adjustments) which are, in the opinion of management, necessary to present fairly the unaudited condensed consolidated financial information required herein. Certain information and note disclosures normally included in financial statement prepared in accordance with accounting principles generally accepted in the United Statements of America ("US GAAP") have been condensed or omitted pursuant to such rules and regulations. While management believes that the disclosures are adequate to make the information presented not misleading, it is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed with the Security and Exchange Commission for the fiscal year ended June 30, 2018.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company&#8217;s common stock trades on the OTCQB Market under the symbol &#8220;ESMC.&#8221;</font></div></div>
CY2018Q3 us-gaap Reclassifications
Reclassifications
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the September&#160;30, 2017 unaudited condensed consolidated statement of operations have been disaggregated to conform to the current period presentation.</font></div></div>
CY2018Q3 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0000862668-18-000025-index-headers.html Edgar Link pending
0000862668-18-000025-index.html Edgar Link pending
0000862668-18-000025.txt Edgar Link pending
0000862668-18-000025-xbrl.zip Edgar Link pending
esmc-20180930.xml Edgar Link completed
esmc-20180930.xsd Edgar Link pending
esmc-20180930_cal.xml Edgar Link unprocessable
esmc-20180930_def.xml Edgar Link unprocessable
esmc-20180930_lab.xml Edgar Link unprocessable
esmc-20180930_pre.xml Edgar Link unprocessable
esmc_2018930-10kex311.htm Edgar Link pending
esmc_2018930-10kex312.htm Edgar Link pending
esmc_2018930-10kex321.htm Edgar Link pending
esmc_2018930-10kex322.htm Edgar Link pending
esmc_2018930-10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending